USA / 5 Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
USA
USA / 2 Things the Biden Administration can do Now to Lower Costs at the Pharmacy
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower…
USA / Navigating Increasingly Stormy Market Access Waters
Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including…
USA / Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
In Conversation
Gary Zieziula – President & Region Head North America, Kyowa Kirin
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the tremendous growth the affiliate has seen over the past three years on track to become a USD 500 million+ organization within the next year; the exciting products and assets that will continue to drive growth for Kyowa Kirin in North…
USA / FDA Drug Approvals 2020
In 2020, the US FDA’s Center for Drug Evaluation & Research (CDER) approved 53 novel drugs, up from 48 in…
Related Report
USA / Paying for Cell & Gene Therapy: Is the Future Already Here?
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced,…
USA / Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
The Future of Biosimilars in the USA
Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the…
USA / Is Its Innovation Leadership Position At-Risk?
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term…
JP Morgan 2021 / A Course Correction for Future Meetings
David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual…
USA / 5 Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
USA / Takeda’s Ramona Sequeira Talks “Culture as Strategy”
After five years with Takeda heading up the Japan-headquartered pharma company’s US business, following the…
Mid-Cap Strategies / LFB USA CEO Optimistic on Hemophilia Launches Amid COVID Crisis
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
USA: The Biosimilars Trade Opportunity
Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable…
USA / 2 Things the Biden Administration can do Now to Lower Costs at the Pharmacy
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why…
Novavax / From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm…
Alzheimer's / Aducanumab: On the Regulatory Home Stretch in the USA
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment…
Norway / Photocure: Swimming in the “Blue Ocean” of Oncology Drug-Device Combinations
Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare…
Switzerland / ISREC’s Susan Gasser: A “Hard-Nosed” Approach to Research Quality & Excellence
After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even…
USA / Can the USA's Fragmented Healthcare System Become More Patient-Centric?
US healthcare is often seen as a fragmented system of contrasts. The country has the highest healthcare…
Indian Generics in the USA / Destined for More Success?
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…